Brionna Mendoza

A brain puzzle against an orange background

News

Most Patients With Schizophrenia Relapse-Free With Paliperidone Palmitate, Open Label Extension Study Finds

08/01/2024

In a 2-year open-label extension study of a 1-year randomized clinical trial, 95.6% of the participating patients with schizophrenia being treated with paliperidone palmitate (PP) remained relapse free for up to 3 years.

In a 2-year open-label extension...

08/01/2024

Psych Congress Network

News

Moderate Physical Activity May Mitigate ALS Risk for Male Patients

07/25/2024

Brionna Mendoza ;

Male individuals who engage in moderate physical activity and fitness may lower their risk for amyotrophic lateral sclerosis (ALS) later in life, according to study findings published in Neurology.

Male individuals who engage in...

07/25/2024

Neurology

News

FDA Declines to Approve OX124 Nasal Spray for Opioid Overdose Treatment

07/23/2024

Brionna Mendoza ;

The US Food and Drug Administration (FDA) has again declined Swedish drug manufacturer Orexo’s New Drug Application (NDA) for OX125, a high-dose naloxone nasal spray for opioid overdose reversal.

The US Food and Drug...

07/23/2024

Psych Congress Network

an illustration of a person sitting on the ground looking dejected

News

Extended-Release Ketamine Tablets May Improve Safety and Tolerability in TRD Treatment

07/12/2024

Brionna Mendoza ;

Racemic ketamine administered as an extended-release tablet (R-107) may offer a treatment option with improved safety and tolerability for patients with treatment-resistant depression (TRD).

Racemic ketamine administered as...

07/12/2024

Psych Congress Network

The US Food and Drug Administration headquarters sign.

FDA Approves Donanemab for Early Alzheimer Disease Treatment

07/02/2024

Brionna Mendoza ;

The US Food and Drug Administration has issued a highly-anticipated decision: the approval of donanemab—to be marketed as Kisunla by manufacturer Eli Lilly—for the treatment of early Alzheimer disease.

The US Food and Drug...

07/02/2024

Psych Congress Network

News

FDA Rejects Parkinson Drug Due to 3rd-Party Manufacturing Concerns

07/02/2024

Brionna Mendoza ;

The US Food and Drug Administration (FDA) rejected AbbVie’s ABBV-95 (foscarbidopa/foslevodopa) last week, raising concerns via complete response letter (CRL) regarding the inspection of a third-party manufacturer listed in the drug...

The US Food and Drug...

07/02/2024

Neurology